Novartis CEO warns US drug pricing policy will impact innovation and patient access soon

Novartis CEO Vas Narasimhan warned that the US drug pricing policy under President Trump creates a challenging environment for drugmakers and patients. He emphasized that if European and Japanese governments do not change how they reward innovation, novel medicines may face delayed market entry, limiting patient access. The CEO highlighted that the effects of the Most Favored Nation (MFN) policy will become clear within the next 18 months, signaling significant long-term implications for the pharmaceutical industry and healthcare.